Bases moleculares de la enfermedad de Alzheimer. Perspectivas de nuevos enfoques terapéuticos
DOI:
https://doi.org/10.5377/encuentro.v0i78.3668Abstract
EL ESTUDIO DE LA ENFERMEDAD DE ALZHEIMER HA AVANZADO mucho en los últimos años gracias al descubrimiento de los genes implicados, sus mutaciones y variantes. Este cúmulo de conocimientos se ha ido organizando en diferentes hipótesis que dan mayor importancia a uno u otro factor genético. Con el progreso acelerado de la fármaco-genómica, se han identificado nuevos factores genéticos de los procesos patogénicos, lo cual debería conllevar a nuevas formas de tratamiento. En este artículo de revisión abordamos las bases moleculares y genéticas del mal de Alzheimer y discutimos las posibles nuevas terapias.
The study of Alzheimer’s Disease (AD) has advanced much in the last few years, thanks to the discovery of associated genes and their variants and mutations. This accumulation of knowledge has led to the creation of various hypotheses concerning AD which give greater relevance to one or other genetic factor. With the accelerated pace of development in the area of pharmaceutical genomics, new genetic factors involved in the pathogenic process have been identified, which should lead to new avenues for treatment. In this review article we discuss the molecular and genetic bases for AD as well as potential new therapies.
Downloads
1131
Downloads
Published
How to Cite
Issue
Section
License
All published articles are licensed under the Creative Commons (BY, NC, SA), in the following terms: no commercial use of the original work or any derivative works, distribution of which must be done with a license equal to that which regulates the original work. This does not condition that the authors maintain their rights without restrictions. The journal allows authors to retain publication rights without restrictions.
![Creative Commons License](https://i.creativecommons.org/l/by-nc-sa/4.0/88x31.png)
Encuentro is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.